综述:免疫检查点抑制剂与肝脏——从治疗疗效到副作用
本文综述了近5年肝病学会议文献,探讨免疫检查点抑制剂在病毒性肝炎和原发性肝癌中的应用及肝脏免疫相关不良反应。肝细胞癌和慢性乙型肝炎近期最具治疗潜力,但肝脏免疫相关不良事件随广泛使用日益受关注,需警惕潜在严重免疫反应。
要点
- 免疫检查点抑制剂在肝细胞癌和慢性乙型肝炎中近期治疗潜力最大。
- 肝脏是免疫检查点抑制剂最常累及的器官之一,需关注免疫相关不良事件。
- 免疫检查点抑制剂在恶性及非恶性肝病中应用目前仍有限。
核心结论
- 免疫检查点抑制剂是一类令人兴奋的新药,目前在恶性及非恶性肝病中应用有限。
- 必须警惕潜在严重免疫不良反应的出现。
研究设计与样本
- 综述近5年肝病学重要会议上关于免疫检查点抑制剂的文献及摘要/报告。
主要发现
- 免疫检查点抑制剂在病毒性肝炎和原发性肝癌的治疗中均有研究。
- 肝细胞癌和慢性乙型肝炎近期最具治疗潜力。
- 肝脏免疫相关不良事件随广泛使用日益受关注。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors have revolutionised the oncological landscape in the last few years. Possible applications include the treatment of hepatocellular carcinoma and cholangiocarcinoma. Unfortunately, new immune-related adverse effects have been associated with the use of these agents and the liver is one of the organs most frequently involved. AIMS: To provide a general overview of the potential impact of immune checkpoint inhibitors on the liver METHODS: We reviewed the literature and abstracts/presentations on immune checkpoint inhibitors at most relevant hepatology meetings over the last 5 years. RESULTS: The role of immune checkpoint inhibitors has been investigated both for the treatment of viral hepatitis and primary liver cancer. Hepatocellular carcinoma and chronic hepatitis B show the greatest potential for treatment with these drugs in the near future. However, immune-related adverse events involving the liver are a growing concern related to their widespread use. CONCLUSIONS: Immune checkpoint inhibitors represent an exciting new class of drugs with currently limited application in malignant and non-malignant liver disease. Caution must be exercised on the emergence of potentially severe immune adverse reactions.
引用
- Lombardi A, Mondelli MU. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. Aliment Pharmacol Ther. 2019. PMID: 31378985. doi:10.1111/apt.15449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。